Bulletin
Investor Alert

New York Markets Open in:

Perrigo Co. PLC

NYS: PRGO

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

May 6, 2021, 7:27 p.m.

/zigman2/quotes/201110862/composite

$

42.72

Change

+0.07 +0.16%

Volume

Volume 117,834

Quotes are delayed by 20 min

/zigman2/quotes/201110862/composite

Previous close

$ 42.02

$ 42.65

Change

+0.63 +1.50%

Day low

Day high

$41.13

$42.67

Open

52 week low

52 week high

$38.20

$58.83

Open

Company Description

Perrigo Co. Plc engages in the provision of over-the-counter (OTC) self-care and wellness solutions. It operates through the following segments: Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals. The Consumer Self-Care Americas segment includes the OTC, ...

Perrigo Co. Plc engages in the provision of over-the-counter (OTC) self-care and wellness solutions. It operates through the following segments: Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals. The Consumer Self-Care Americas segment includes the OTC, infant formula, and oral self-care categories; divested animal health category; and contract manufacturing businesses in the U.S., Mexico, and Canada. The Consumer Self-Care International segment consists of the consumer self-care business primarily branded in Europe and Australia; store brand business in the United Kingdom and parts of Europe and Asia; and divested liquid licensed products business in the United Kingdom. The Prescription Pharmaceuticals segment commercializes and manufactures generic prescription products in the U.S. and diagnostic products in Israel. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Valuation

Price to Sales Ratio

1.20

Price to Book Ratio

1.05

Price to Cash Flow Ratio

9.57

Enterprise Value to EBITDA

10.64

Enterprise Value to Sales

1.82

Total Debt to Enterprise Value

0.41

Efficiency

Revenue/Employee

440,261.00

Income Per Employee

-14,139.00

Receivables Turnover

4.32

Total Asset Turnover

0.44

Liquidity

Current Ratio

2.27

Quick Ratio

1.40

Cash Ratio

0.47

Profitability

Gross Margin

35.77

Operating Margin

9.13

Pretax Margin

-2.95

Net Margin

-3.21

Return on Assets

-1.43

Return on Equity

-2.84

Return on Total Capital

4.94

Return on Invested Capital

-1.75

Capital Structure

Total Debt to Total Equity

66.48

Total Debt to Total Capital

39.93

Total Debt to Total Assets

32.72

Long-Term Debt to Equity

65.21

Long-Term Debt to Total Capital

39.17

Officers and Executives

Name Age Officer Since Title
Mr. Murray S. Kessler 60 2018 President, Chief Executive Officer & Director
Mr. Raymond P. Silcock 69 2019 CFO, Principal Accounting Officer & Executive VP
Mr. Thomas Farrington 61 2006 Chief Information Officer & Senior Vice President
Dr. Grainne Quinn 49 2014 Chief Medical Officer & Executive Vice President
Mr. James E. Dillard 55 2019 Chief Scientific Officer & Executive VP

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
04/05/2021 Raymond P. Silcock
EVP, Chief Financial Officer
3,964   Derivative/Non-derivative trans. at $40.39 per share. 160,105
03/17/2021 Geoffrey M. Parker
Director
2,500   Acquisition at $41.29 per share. 103,225
03/10/2021 Ronald C. Janish
EVP, Gbl Ops & SC & CTO
2,662   Disposition at $41.23 per share. 109,754
03/08/2021 Todd W. Kingma
Executive VP, General Counsel
2,166   Derivative/Non-derivative trans. at $41.82 per share. 90,582
03/08/2021 Thomas M. Farrington
EVP and CIO
1,639   Derivative/Non-derivative trans. at $41.82 per share. 68,542
03/08/2021 Ronald C. Janish
EVP, Gbl Ops & SC & CTO
1,179   Derivative/Non-derivative trans. at $41.82 per share. 49,305
03/08/2021 Svend D. Andersen
EVP & President CHCI
47   Derivative/Non-derivative trans. at $41.82 per share. 1,965
03/08/2021 Grainne Quinn
EVP, Chief Medical Officer
1,083   Derivative/Non-derivative trans. at $41.82 per share. 45,291
03/08/2021 Robert Willis
EVP & CHRO
363   Derivative/Non-derivative trans. at $41.82 per share. 15,180
03/08/2021 Robert Willis
EVP & CHRO
980   Derivative/Non-derivative trans. at $41.82 per share. 40,983
03/08/2021 Todd W. Kingma
Executive VP, General Counsel
7,571   Award at $41.82 per share. 316,619
03/08/2021 Sharon Kochan
EVP & President Rx
4,721   Award at $41.82 per share. 197,432
03/08/2021 Thomas M. Farrington
EVP and CIO
3,758   Award at $41.82 per share. 157,159
03/08/2021 Ronald C. Janish
EVP, Gbl Ops & SC & CTO
4,121   Award at $41.82 per share. 172,340
03/08/2021 Svend D. Andersen
EVP & President CHCI
5,543   Award at $41.82 per share. 231,808
03/08/2021 Grainne Quinn
EVP, Chief Medical Officer
2,082   Award at $41.82 per share. 87,069
03/08/2021 Robert Willis
EVP & CHRO
1,884   Award at $41.82 per share. 78,788
03/08/2021 Robert Willis
EVP & CHRO
697   Derivative/Non-derivative trans. at $41.82 per share. 29,148
03/05/2021 Todd W. Kingma
Executive VP, General Counsel
667   Derivative/Non-derivative trans. at $41.04 per share. 27,373
03/05/2021 Todd W. Kingma
Executive VP, General Counsel
777   Derivative/Non-derivative trans. at $41.04 per share. 31,888
03/05/2021 Murray S. Kessler
CEO; Director
5,683   Derivative/Non-derivative trans. at $41.04 per share. 233,230
03/05/2021 Murray S. Kessler
CEO; Director
6,622   Derivative/Non-derivative trans. at $41.04 per share. 271,766
03/05/2021 Murray S. Kessler
CEO; Director
6,623   Derivative/Non-derivative trans. at $41.04 per share. 271,807
03/05/2021 Thomas M. Farrington
EVP and CIO
640   Derivative/Non-derivative trans. at $41.04 per share. 26,265
03/05/2021 Thomas M. Farrington
EVP and CIO
607   Derivative/Non-derivative trans. at $41.04 per share. 24,911
03/05/2021 Ronald C. Janish
EVP, Gbl Ops & SC & CTO
442   Derivative/Non-derivative trans. at $41.04 per share. 18,139
03/05/2021 Ronald C. Janish
EVP, Gbl Ops & SC & CTO
514   Derivative/Non-derivative trans. at $41.04 per share. 21,094
03/05/2021 Svend D. Andersen
EVP & President CHCI
37   Derivative/Non-derivative trans. at $41.04 per share. 1,518
03/05/2021 James E. Dillard
EVP, Chief Scientific Officer
570   Derivative/Non-derivative trans. at $41.04 per share. 23,392
03/05/2021 James E. Dillard
EVP, Chief Scientific Officer
666   Derivative/Non-derivative trans. at $41.04 per share. 27,332
03/05/2021 Grainne Quinn
EVP, Chief Medical Officer
548   Derivative/Non-derivative trans. at $41.04 per share. 22,489
03/05/2021 Grainne Quinn
EVP, Chief Medical Officer
638   Derivative/Non-derivative trans. at $41.04 per share. 26,183
03/05/2021 Robert Willis
EVP & CHRO
496   Derivative/Non-derivative trans. at $41.04 per share. 20,355
03/05/2021 Robert Willis
EVP & CHRO
286   Derivative/Non-derivative trans. at $41.04 per share. 11,737
03/05/2021 Robert Willis
EVP & CHRO
302   Derivative/Non-derivative trans. at $41.04 per share. 12,394
03/05/2021 Todd W. Kingma
Executive VP, General Counsel
2,540   Derivative/Non-derivative trans. at $41.04 per share. 104,241
03/05/2021 Todd W. Kingma
Executive VP, General Counsel
2,960   Derivative/Non-derivative trans. at $41.04 per share. 121,478
03/05/2021 Murray S. Kessler
CEO; Director
14,061   Derivative/Non-derivative trans. at $41.04 per share. 577,063
03/05/2021 Murray S. Kessler
CEO; Director
16,385   Derivative/Non-derivative trans. at $41.04 per share. 672,440
03/05/2021 Murray S. Kessler
CEO; Director
14,061   Derivative/Non-derivative trans. at $41.04 per share. 577,063
03/05/2021 Murray S. Kessler
CEO; Director
16,385   Derivative/Non-derivative trans. at $41.04 per share. 672,440
03/05/2021 Sharon Kochan
EVP & President Rx
1,996   Derivative/Non-derivative trans. at $41.04 per share. 81,915
03/05/2021 Sharon Kochan
EVP & President Rx
2,061   Derivative/Non-derivative trans. at $41.04 per share. 84,583
03/05/2021 Thomas M. Farrington
EVP and CIO
1,261   Derivative/Non-derivative trans. at $41.04 per share. 51,751
03/05/2021 Thomas M. Farrington
EVP and CIO
1,469   Derivative/Non-derivative trans. at $41.04 per share. 60,287
03/05/2021 Ronald C. Janish
EVP, Gbl Ops & SC & CTO
1,542   Derivative/Non-derivative trans. at $41.04 per share. 63,283
03/05/2021 Ronald C. Janish
EVP, Gbl Ops & SC & CTO
1,797   Derivative/Non-derivative trans. at $41.04 per share. 73,748
03/05/2021 Svend D. Andersen
EVP & President CHCI
2,540   Derivative/Non-derivative trans. at $41.04 per share. 104,241
03/05/2021 Svend D. Andersen
EVP & President CHCI
2,960   Derivative/Non-derivative trans. at $41.04 per share. 121,478
03/05/2021 Richard S. Sorota
EVP & President CSCA
2,540   Derivative/Non-derivative trans. at $41.04 per share. 104,241
03/05/2021 James E. Dillard
EVP, Chief Scientific Officer
1,996   Derivative/Non-derivative trans. at $41.04 per share. 81,915
03/05/2021 James E. Dillard
EVP, Chief Scientific Officer
2,326   Derivative/Non-derivative trans. at $41.04 per share. 95,459
03/05/2021 Raymond P. Silcock
EVP, Chief Financial Officer
3,629   Derivative/Non-derivative trans. at $41.04 per share. 148,934
03/05/2021 Grainne Quinn
EVP, Chief Medical Officer
1,053   Derivative/Non-derivative trans. at $41.04 per share. 43,215
03/05/2021 Grainne Quinn
EVP, Chief Medical Officer
1,226   Derivative/Non-derivative trans. at $41.04 per share. 50,315
03/05/2021 Robert Willis
EVP & CHRO
953   Derivative/Non-derivative trans. at $41.04 per share. 39,111
03/05/2021 Robert Willis
EVP & CHRO
550   Derivative/Non-derivative trans. at $41.04 per share. 22,572
03/05/2021 Robert Willis
EVP & CHRO
580   Derivative/Non-derivative trans. at $41.04 per share. 23,803
03/05/2021 Murray S. Kessler
CEO; Director
5,683   Derivative/Non-derivative trans. at $41.04 per share. 233,230
03/05/2021 Svend D. Andersen
EVP & President CHCI
55   Derivative/Non-derivative trans. at $41.04 per share. 2,257
03/05/2021 Richard S. Sorota
EVP & President CSCA
1,108   Derivative/Non-derivative trans. at $41.04 per share. 45,472
02/05/2021 James E. Dillard
EVP, Chief Scientific Officer
1,396   Derivative/Non-derivative trans. at $43.09 per share. 60,153
02/05/2021 James E. Dillard
EVP, Chief Scientific Officer
4,297   Derivative/Non-derivative trans. at $0 per share. 0
01/06/2021 Richard S. Sorota
EVP & President CSCA
7,513   Acquisition at $43.48 per share. 326,665
11/09/2020 Theodore Rapp Samuels
Director
4,500   Acquisition at $46.91 per share. 211,095
11/09/2020 Rolf Allan Classon
Director
2,137   Acquisition at $46.75 per share. 99,904
08/14/2020 Robert Willis
EVP & CHRO
303   Derivative/Non-derivative trans. at $53.4 per share. 16,180
08/14/2020 Robert Willis
EVP & CHRO
581   Derivative/Non-derivative trans. at $53.4 per share. 31,025
08/11/2020 Svend D. Andersen
EVP & President CHCI
2,828   Acquisition at $53.01 per share. 149,912
/news/latest/company/us/prgo

MarketWatch News on PRGO

  1. Perrigo Co. PLC stock outperforms market on strong trading day

    5:17 p.m. May 6, 2021

    - MarketWatch Automation

  2. Perrigo Co. PLC stock outperforms competitors despite losses on the day

    5:17 p.m. May 5, 2021

    - MarketWatch Automation

  3. Perrigo Co. PLC stock falls Tuesday, still outperforms market

    5:17 p.m. May 4, 2021

    - MarketWatch Automation

  4. Perrigo Co. PLC stock rises Monday, outperforms market

    5:18 p.m. May 3, 2021

    - MarketWatch Automation

  5. Perrigo Co. PLC stock falls Friday, underperforms market

    5:17 p.m. April 30, 2021

    - MarketWatch Automation

  6. Perrigo Co. PLC stock rises Thursday, outperforms market

    5:17 p.m. April 29, 2021

    - MarketWatch Automation

  7. Perrigo Co. PLC stock rises Wednesday, outperforms market

    5:17 p.m. April 28, 2021

    - MarketWatch Automation

  8. Perrigo Co. PLC stock outperforms competitors despite losses on the day

    5:17 p.m. April 27, 2021

    - MarketWatch Automation

  9. Perrigo Co. PLC stock outperforms market on strong trading day

    5:17 p.m. April 26, 2021

    - MarketWatch Automation

  10. It’s Time for Perrigo’s Stock to Turn Around

    11:39 a.m. April 26, 2021

    - Barron's Online

  11. Perrigo Co. PLC stock underperforms Friday when compared to competitors

    5:17 p.m. April 23, 2021

    - MarketWatch Automation

  12. Perrigo Co. PLC stock outperforms market despite losses on the day

    5:17 p.m. April 22, 2021

    - MarketWatch Automation

  13. Perrigo Co. PLC stock outperforms market on strong trading day

    5:17 p.m. April 21, 2021

    - MarketWatch Automation

  14. Perrigo Co. PLC stock outperforms market on strong trading day

    5:17 p.m. April 20, 2021

    - MarketWatch Automation

  15. Perrigo Co. PLC stock outperforms market on strong trading day

    5:17 p.m. April 19, 2021

    - MarketWatch Automation

  16. A Smart Way to Play the Pet-Care Industry’s Boom

    10:46 a.m. April 19, 2021

    - Barron's Online

  17. Perrigo Co. PLC stock rises Friday, outperforms market

    5:17 p.m. April 16, 2021

    - MarketWatch Automation

  18. Perrigo Co. PLC stock outperforms market on strong trading day

    5:17 p.m. April 15, 2021

    - MarketWatch Automation

  19. Perrigo Co. PLC stock outperforms market on strong trading day

    5:18 p.m. April 14, 2021

    - MarketWatch Automation

  20. Perrigo Co. PLC stock underperforms Tuesday when compared to competitors

    5:18 p.m. April 13, 2021

    - MarketWatch Automation

  21. Loading more headlines...
/news/nonmarketwatch/company/us/prgo

Other News on PRGO

  1. Undervalued Perrigo Is A Dividend Stock to Have And to Hold

    3:17 p.m. May 4, 2021

    - InvestorPlace.com

  2. Perrigo - Simplifying To Unlock Appeal

    2:14 a.m. May 2, 2021

    - Seeking Alpha

  3. Wall Street Breakfast: The Week Ahead

    7:01 a.m. April 25, 2021

    - Seeking Alpha

  4. What's in Store for Perrigo (PRGO) This Earnings Season?

    9:43 a.m. April 23, 2021

    - Zacks.com

  5. Perrigo: An Underperformer In Transition

    2:10 a.m. April 14, 2021

    - Seeking Alpha

  6. Green's Portfolio - March 2021

    9:51 p.m. April 4, 2021

    - Seeking Alpha

  7. Dividend Champion And Contender Highlights: Week Of March 28

    3:43 p.m. March 27, 2021

    - Seeking Alpha

  8. Dividend Champion And Contender Highlights: Week Of March 7

    2:11 p.m. March 6, 2021

    - Seeking Alpha

  9. 27 Upcoming Dividend Increases Including This Dividend King

    9:50 a.m. March 4, 2021

    - Seeking Alpha

  10. Leerink Partners Releases a Buy Rating on Perrigo Company (PRGO)

    9:48 a.m. March 2, 2021

    - SmarterAnalyst

  11. Perrigo Company (PRGO) Receives a Hold from Raymond James

    4:36 p.m. March 1, 2021

    - SmarterAnalyst

  12. 10-K: PERRIGO CO PLC

    3:56 p.m. March 1, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  13. Dividend Champions For March 2021

    2:08 p.m. March 1, 2021

    - Seeking Alpha

  14. Perrigo stock surges despite Q4 beats consensus

    11:10 a.m. March 1, 2021

    - Seeking Alpha

  15. Perrigo (PRGO) Misses on Q4 Earnings, to Sell Generic Unit

    10:33 a.m. March 1, 2021

    - Zacks.com

  16. Perrigo (PRGO) Q4 Earnings and Revenues Lag Estimates

    8:25 a.m. March 1, 2021

    - Zacks.com

  17. Loading more headlines...

At a Glance

Perrigo Co. Plc

The Sharp Building

Hogan Place

Dublin, Dublin 2

Phone

353 17094000

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$5.06B

Net Income

$-162.60M

2020 Sales Growth

4.7%

Employees

11,500

/news/pressrelease/company/us/prgo

Press Releases on PRGO

  1. Loading more headlines...
Link to MarketWatch's Slice.